

# Histiocytosis and targeted therapies in 2019

European and Mediterranean seminar

Saturday April 6 th 2019, 9 h 30 -17 h 30

Location: Cité Universitaire : 17 boulevard Jourdan, 75014 Paris, France

Meeting room / Pavillon du Cambodge Métro Cité Universitaire RER B

<http://www.ciup.fr/>

## ○ MORNING : 9 h 30 -13 h

### Introduction:

Molecular basis of *Histiocytosis*: Before Braf and now: JF Emile 15'

Medical needs in histiocytosis 35'

Langerhans cell histiocytosis 10' M Minkov, Vienna  
Erdheim Chester disease 10' J Haroche  
Juvenile Xantho granuloma 5' S Héritier  
Rosai Dorfman Disease 5' F Cohen  
Malignant Histiocytosis 5' S Héritier

The cell of origins and its clinical implication 40'

Bone marrow as a reservoir of mutated macrophages: M Collins, Newcastle 20'

Resident macrophages and yolk salk derived macrophages: F Geissmann, NY 20'

### Pause: 15 minutes

### Targeted therapies:

2014 – 2019: First evidences 90'

LCH : European experiences : J Donadieu, TRS 15'  
ECD : J Haroche, Pitié 15'  
Rosai Dorfman : F Cohen, Pitié 10'  
JXG Malignant Histicoytosis: S Héritier, TRS 10'  
Side effects of targeted therapies skin and more: M Tardieu, Grenoble 10'  
Pharmacology of targeted drugs: what is important? A Larabi, Garches 10'  
Point of view of ROCHE 10'  
Point of view of Novartis 10'

### Lunch on site: 13 h - 13 h 45

The participation to the seminar is free. But please inform us of your participation by mail at the following address to adapt the logistic. Please contact us if you look for assistance for hosting at the same address.

[secretariat.histiocytose@gmail.com](mailto:secretariat.histiocytose@gmail.com)

## AFTERNOON: 13h 45 - 17h

### Round table n°1: 13 h 45 - 14 h 45

Toward a consensus for bio monitoring  
Braf load in the blood, urine, bone marrow as a surrogate marker

Each team will present their results in 10'  
the French team (V Taly S Heritier, Z Hélias), UK (P Milne M Collins), Netherlands (A Van Halteren), Austria(C Hutter).

### Round table n°2: 15 h 45 - 16 h 45

Neurodegeneration in Histiocytosis :  
Prevention and treatment

What animal model suggest : F Geissmann  
Defining a risk group : S Héritier  
Results of therapies in ND LCH: A Idbah  
Is it time for pre emptive approach?: M Minkov, J Visser, C Van Den Bosh, J Donadieu, E Sieni

### Round table n° 3: 16 h 45 - 17 h 30

Cure histiocytosis: proposal for a maintenance beyond initial targeted therapy

All participants. Short introduction J Haroche (ECD) J Donadieu (LCH)

### Conclusion: CURE HISTIO 2019 ?

**The participation to the seminar is free. But please informed us of your participation in order by mail at the following address to adapt the logistic. Please contact us if you look for assistance for hosting at the same adress.**  
[secretariat.histiocytose@gmail.com](mailto:secretariat.histiocytose@gmail.com)